Wells Fargo analyst Tiago Fauth maintains Aerovate Therapeutics (NASDAQ:AVTE) with a Overweight and maintains $35 price target.
Wells Fargo Maintains Overweight on Aerovate Therapeutics, Maintains $35 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.